← Back to Clinical Trials
Recruiting NCT04844151

NCT04844151 Acute Myocarditis Registry With Prognostic, Histologic, Immunologic, Biological, Imaging and Clinical Assessment

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04844151
Status Recruiting
Phase
Sponsor Assistance Publique - Hôpitaux de Paris
Condition Myocarditis
Study Type OBSERVATIONAL
Enrollment 1,400 participants
Start Date 2022-01-23
Primary Completion 2041-05-01

Eligibility & Interventions

Sex All sexes
Min Age 15 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 1,400 participants in total. It began in 2022-01-23 with a primary completion date of 2041-05-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The AMPHIBIA study is an observational ambispective and prospective cohort that aim to describe the histologic, immunologic, biological, imaging, genetic and clinical characteristics of the patients hospitalized for an acute myocarditis and to evaluate their association with prognosis.

Eligibility Criteria

Inclusion Criteria: * Acute myocarditis confirmed by cardiac magnetic resonance according to Lake Louise modified criteria or by endomyocardial biopsy according to histologic, immunologic and immunohistochemic criteria. * affiliation to the French Health Care System "Sécurité sociale" Exclusion Criteria: * Severe valvulopathy * Complex congenital cardiopathy * Previous heart transplant * Known significative coronary disease

Contact & Investigator

Central Contact

Mathieu Kerneis, MD

✉ mathieu.kerneis@aphp.fr

📞 +33142163001

Principal Investigator

Giles MONTALESCOT, MD, PhD

STUDY DIRECTOR

ACTION Study Group - Assistance Publique - Hôpitaux de Paris

Frequently Asked Questions

Who can join the NCT04844151 clinical trial?

This trial is open to participants of all sexes, aged 15 Years or older, studying Myocarditis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04844151 currently recruiting?

Yes, NCT04844151 is actively recruiting participants. Contact the research team at mathieu.kerneis@aphp.fr for enrollment information.

Where is the NCT04844151 trial being conducted?

This trial is being conducted at Paris, France.

Who is sponsoring the NCT04844151 clinical trial?

NCT04844151 is sponsored by Assistance Publique - Hôpitaux de Paris. The principal investigator is Giles MONTALESCOT, MD, PhD at ACTION Study Group - Assistance Publique - Hôpitaux de Paris. The trial plans to enroll 1,400 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology